Please assess the completion status of the following clinical trial:

Trial Title: Cryotherapy in the Prevention of Chemotherapy-Induced Mucositis in Stem Cell Transplant

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects age 18 year old or older who are eligible candidates for myeloablative autologous stem cell transplantation (ASCT).~* Subjects receiving etoposide as part of their conditioning regimen with a planned total dose of ≥ 30 mg/kg.~Exclusion Criteria:~* Subjects with prior radiation to head \& neck region.~* Subjects with known oropharynx involvement with their malignancy.~* Subjects with a history of non-compliance or who lack capacity to give informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Cryotherapy Group (Group A) (Type: ACTIVE_COMPARATOR): Subjects in the intervention group will receive both standard oral care and cryotherapy. During the 30 minute cryotherapy periods, subjects will eat ice chips, and/or consume very cold or frozen foods. Cryotherapy will begin 15 minutes prior to the start time of each etoposide infusion. After 30 minutes of cryotherapy, subjects will begin the saline rinses. The subject should perform 3 saline rinses over 15 minutes. After 15 minutes of saline rinses, the 30-minute cryotherapy / 15-minute saline rinse cycles will be repeated until 30 min after completion of etoposide infusion (approximately 150 minutes). In addition, an oral care diary will be completed by the subject, and a daily oral assessment will be performed by the investigators.
- Standard Oral Care Group (Group B) (Type: ACTIVE_COMPARATOR): Subjects in the control group will receive standard oral care only. At the beginning of each etoposide infusion, the subject will begin the saline rinses. The subject will perform 3 saline rinses over 15 minutes followed by 30 minutes of rest (no rinses). The 15-minute saline rinse / 30-minute rest cycles will be repeated until 30 minutes after the completion of the etoposide infusion (approximately 150 minutes). In addition, an oral care diary will be completed by the subject, and a daily oral assessment will be performed by the investigators.

Based on this trial design, predict the completion outcome and termination type (if applicable).